Candida albicans vaccine - LigoCyteAlternative Names: CAV-6.1
Latest Information Update: 05 Feb 2007
At a glance
- Originator LigoCyte Pharmaceuticals
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Candidiasis
Most Recent Events
- 14 Jul 2004 This programme is still in active development - BIO 2004 Annual International Convention (BIO-2004)
- 30 Jul 2002 This programme is still in active development
- 15 Oct 1999 Preclinical development for Candidiasis in USA (Unknown route)